Seroresponse rates for MenQuadfi were noninferior to those of Menactra for all serogroups based on the same non-inferiority criteria defined for Study 2. Immunogenicity in Adults 18 through 55 Years of Age Immunogenicity of MenQuadfi compared to Menactra in participants 18 through 55 years of ...
‡The overall non-inferiority would be demonstrated if the lower limit of the 2-sided 95% CI is > -10% for all four serogroups. Immunogenicity In Adults 56 Years Of Age And Older Immunogenicity of MenQuadfi compared to Menomune in participants 56 years and older was evaluated in Study 4...